Coherus BioSciences Shares Climb 12% on FDA Approval for Cancer Treatment Loqtorzi
October 27 2023 - 5:55PM
Dow Jones News
By Sabela Ojea
Shares of Coherus BioSciences climbed 12% to $2.96 in
after-hours trading after the company said the Food and Drug
Administration approved Loqtorzi to treat nasopharyngeal cancer
when used with chemotherapy.
The biotechnology company said Friday that Loqtorzi is aimed at
patients with metastatic nasopharyngeal cancer.
The FDA backed Loqtorzi, set to be commercially available in the
U.S. in the first quarter of 2024, in combination with chemotherapy
drugs cisplatin and gemcitabine.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
October 27, 2023 17:40 ET (21:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Jul 2023 to Jul 2024
